Literature DB >> 12452846

Autoantibodies against small nucleolar ribonucleoprotein complexes and their clinical associations.

H Van Eenennaam1, J H P Vogelzangs, L Bisschops, L C J Te Boome, H P Seelig, M Renz, D-J De Rooij, R Brouwer, H Pluk, G J M Pruijn, W J Van Venrooij, F H J Van Den Hoogen.   

Abstract

Sera from patients suffering from systemic autoimmune diseases such as systemic lupus erythematosus (SLE) and systemic sclerosis (SSc) have been shown to contain reactivities to nuclear components. Autoantibodies specifically targeting nucleolar antigens are found most frequently in patients suffering from SSc or SSc overlap syndromes. We determined the prevalence and clinical significance of autoantibodies directed to nucleolar RNA-protein complexes, the so-called small nucleolar ribonucleoprotein complexes (snoRNPs). A total of 172 patient sera with antinucleolar antibodies were analysed by immunoprecipitation. From 100 of these patients clinical information was obtained by chart review. Autoantibodies directed to snoRNPs were detected not only in patients suffering from SSc and primary Raynaud's phenomenon (RP), but also in patients suffering from SLE, rheumatoid arthritis (RA) and myositis (PM/DM). Antibodies against box C/D small snoRNPs can be subdivided in antifibrillarin positive and antifibrillarin negative reactivity. Antifibrillarin-positive patient sera were associated with a poor prognosis in comparison with antifibrillarin negative (reactivity with U3 or U8 snoRNP only) patient sera. Anti-Th/To autoantibodies were associated with SSc, primary RP and SLE and were found predominantly in patients suffering from decreased co-diffusion and oesophagus motility and xerophthalmia. For the first time autoantibodies that recognize box H/ACA snoRNPs are described, identifying this class of snoRNPs as a novel autoantigenic activity. Taken together, our data show that antinucleolar patient sera directed to small nucleolar ribonucleoprotein complexes are found frequently in other diseases than SSc and that categorization of diagnoses and clinical manifestations based on autoantibody profiles seems particularly informative in patient sera recognizing box C/D snoRNPs.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12452846      PMCID: PMC1906554          DOI: 10.1046/j.1365-2249.2002.01991.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  47 in total

1.  Imp3p and Imp4p, two specific components of the U3 small nucleolar ribonucleoprotein that are essential for pre-18S rRNA processing.

Authors:  S J Lee; S J Baserga
Journal:  Mol Cell Biol       Date:  1999-08       Impact factor: 4.272

Review 2.  Autoantibodies in scleroderma.

Authors:  K M Pollard; G Reimer; E M Tan
Journal:  Clin Exp Rheumatol       Date:  1989 Sep-Oct       Impact factor: 4.473

3.  The analysis of antinuclear and antinucleolar autoantibodies of scleroderma by radioimmunoprecipitation assays.

Authors:  R J Kipnis; J Craft; J A Hardin
Journal:  Arthritis Rheum       Date:  1990-09

4.  The RNA processing enzyme RNase MRP is identical to the Th RNP and related to RNase P.

Authors:  H A Gold; J N Topper; D A Clayton; J Craft
Journal:  Science       Date:  1989-09-22       Impact factor: 47.728

5.  Identification and characterization of an RNA molecule that copurifies with RNase P activity from HeLa cells.

Authors:  M Bartkiewicz; H Gold; S Altman
Journal:  Genes Dev       Date:  1989-04       Impact factor: 11.361

6.  Autoantibody to Th ribonucleoprotein (nucleolar 7-2 RNA protein particle) in patients with systemic sclerosis.

Authors:  Y Okano; T A Medsger
Journal:  Arthritis Rheum       Date:  1990-12

7.  Immunolocalization of 7-2-ribonucleoprotein in the granular component of the nucleolus.

Authors:  G Reimer; I Raska; U Scheer; E M Tan
Journal:  Exp Cell Res       Date:  1988-05       Impact factor: 3.905

8.  Detection of a nucleolar 7-2 ribonucleoprotein and a cytoplasmic 8-2 ribonucleoprotein with autoantibodies from patients with scleroderma.

Authors:  R Reddy; E M Tan; D Henning; K Nohga; H Busch
Journal:  J Biol Chem       Date:  1983-02-10       Impact factor: 5.157

9.  Correlates between autoantibodies to nucleolar antigens and clinical features in patients with systemic sclerosis (scleroderma).

Authors:  G Reimer; V D Steen; C A Penning; T A Medsger; E M Tan
Journal:  Arthritis Rheum       Date:  1988-04

10.  Antibodies in human serum that precipitate ribonuclease P.

Authors:  H A Gold; J Craft; J A Hardin; M Bartkiewicz; S Altman
Journal:  Proc Natl Acad Sci U S A       Date:  1988-08       Impact factor: 11.205

View more
  16 in total

Review 1.  Autoantibodies as predictive tools in systemic sclerosis.

Authors:  Svetlana I Nihtyanova; Christopher P Denton
Journal:  Nat Rev Rheumatol       Date:  2010-02       Impact factor: 20.543

Review 2.  Anti-nuclear autoantibodies in systemic sclerosis : News and perspectives.

Authors:  Yasuhito Hamaguchi; Kazuhiko Takehara
Journal:  J Scleroderma Relat Disord       Date:  2018-07-10

Review 3.  Clinical Significance of Antinucleolar Antibodies: Biomarkers for Autoimmune Diseases, Malignancies, and others.

Authors:  Minoru Satoh; Angela Ceribelli; Tomoko Hasegawa; Shin Tanaka
Journal:  Clin Rev Allergy Immunol       Date:  2022-03-08       Impact factor: 10.817

Review 4.  Autoantibodies in systemic sclerosis (scleroderma): clues for clinical evaluation, prognosis and pathogenesis.

Authors:  Alfred Grassegger; Gabriela Pohla-Gubo; Margret Frauscher; Helmut Hintner
Journal:  Wien Med Wochenschr       Date:  2008

Review 5.  Antibodies in scleroderma: direct pathogenicity and phenotypic associations.

Authors:  Lorinda Chung; Paul J Utz
Journal:  Curr Rheumatol Rep       Date:  2004-04       Impact factor: 4.592

Review 6.  Toxicology of autoimmune diseases.

Authors:  K Michael Pollard; Per Hultman; Dwight H Kono
Journal:  Chem Res Toxicol       Date:  2010-03-15       Impact factor: 3.739

Review 7.  The clinical relevance of autoantibodies in scleroderma.

Authors:  Khanh T Ho; John D Reveille
Journal:  Arthritis Res Ther       Date:  2003-02-12       Impact factor: 5.156

8.  Rpp25 is a major target of autoantibodies to the Th/To complex as measured by a novel chemiluminescent assay.

Authors:  Michael Mahler; Cristina Gascon; Sima Patel; Angela Ceribelli; Marvin J Fritzler; Andreas Swart; Edward K L Chan; Minoru Satoh
Journal:  Arthritis Res Ther       Date:  2013-04-12       Impact factor: 5.156

Review 9.  The use and abuse of commercial kits used to detect autoantibodies.

Authors:  Marvin J Fritzler; Allan Wiik; Mark L Fritzler; Susan G Barr
Journal:  Arthritis Res Ther       Date:  2003-06-09       Impact factor: 5.156

Review 10.  Bench to bedside review of myositis autoantibodies.

Authors:  Boaz Palterer; Gianfranco Vitiello; Alessia Carraresi; Maria Grazia Giudizi; Daniele Cammelli; Paola Parronchi
Journal:  Clin Mol Allergy       Date:  2018-03-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.